157 354

Cited 20 times in

Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial

DC Field Value Language
dc.contributor.author김지현-
dc.date.accessioned2017-10-26T07:20:01Z-
dc.date.available2017-10-26T07:20:01Z-
dc.date.issued2016-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/151890-
dc.description.abstractBACKGROUND/AIMS: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. METHODS: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were compared among the two regimens. RESULTS: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. CONCLUSIONS: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherEditorial Office of Gut and Liver-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAmoxicillin/administration & dosage-
dc.subject.MESHAnti-Bacterial Agents/administration & dosage*-
dc.subject.MESHClarithromycin/administration & dosage-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHelicobacter Infections/drug therapy*-
dc.subject.MESHHelicobacter pylori/drug effects*-
dc.subject.MESHHumans-
dc.subject.MESHIntention to Treat Analysis-
dc.subject.MESHMale-
dc.subject.MESHMedication Adherence-
dc.subject.MESHMetronidazole/administration & dosage-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProton Pump Inhibitors/administration & dosage*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTreatment Outcome-
dc.titleSequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial-
dc.typeArticle-
dc.publisher.locationKorea (South)-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJoon Sung Kim-
dc.contributor.googleauthorByung-Wook Kim-
dc.contributor.googleauthorSu Jin Hong-
dc.contributor.googleauthorJin Il Kim-
dc.contributor.googleauthorKi-Nam Shim-
dc.contributor.googleauthorJie-Hyun Kim-
dc.contributor.googleauthorGwang Ho Baik-
dc.contributor.googleauthorSang Wook Kim-
dc.contributor.googleauthorHyun Joo Song-
dc.contributor.googleauthorJi Hyun Kim-
dc.identifier.doi10.5009/gnl15470-
dc.contributor.localIdA00996-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid27114421-
dc.subject.keywordDisease eradication-
dc.subject.keywordDrug resistance-
dc.subject.keywordHelicobacter pylori-
dc.contributor.alternativeNameKim, Ji Hyun-
dc.contributor.affiliatedAuthorKim, Ji Hyun-
dc.citation.volume10-
dc.citation.number4-
dc.citation.startPage556-
dc.citation.endPage561-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.10(4) : 556-561, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid46215-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.